Menu

photo of Sheldon Landesman

Sheldon H. Landesman, MD

Professor of Medicine
Assistant Dean for Clinical Education
Director, Essentials of Clinical Medicine Programs

Dr. Landesman graduated from Downstate in 1972 and completed fellowship training for Hematology-Oncology at the National Cancer Institute and Infectious Diseases at Tufts University. Following his return to SUNY-Downstate he was at the forefront of the HIV/AIDS epidemic and was involved in research examining perinatal transmission of HIV. Dr. Landesman has worked with the NYC Department of Health during outbreaks of tuberculosis.  He is well published and has been the recipient of many NIH funded grants. Dr. Landesman is now partially retired and works primarily in medical education.

Research Interests:

perinatal HIV, ethics related to HIV Current projects: collaborator -perinatal HIV study

Education and Training:
  • Medical School: Downstate
  • Internship: NYU-Bellvue Hospital Center
  • Fellowship: National Cancer Institute, Hematology and Oncology
  • Residency: Tufts,New England Medical Center, Boston, Mass.
  • Fellowship: Infectious Disease, Tufts, New England Medical Center
Why I enjoy working at SUNY Downstate:

the students, the diversity and spectrum of clinical disease, my fellow ID faculty, short drive to work

Mailing Address:
450 Clarkson Ave, MSC 1245
Brooklyn, NY 11415

  • Landesman SH. , Kalish L, Burns D, Minkoff H, Fox H, et al.: Obstetrical Factors and the Transmission of HIV type 1 from mother to child. New England Journal of Medicine, 1996;334:1617-23Kalish LA, Pitt J, Lew J, Landesman SH, et al. Defining the time of Fetal orPerinatal Acquisition of HIV-1 Infection Based on Age of First Positive Culture. J Infec Dis, 1997; 175:712-5.
  • Burns D, Landesman SH, et al. Influence of Other Maternal Variables on the Relationship between Maternal Virus Load and Mother-to-Infant Transmission ofHIV Type 1. J Infec Dis, 1997;175:1206-10
  • Bayer R, Stayton C, Desvarieux M, Healton C, and Landesman S. Directly Observed Terapy and Treatment Completions for Tuberculosis in the United States - 1990-1994 Am Journal of Public Health1998; 88(7):1052-8
  • The International Perinatal HIV Group (Landesman SH member of writing committee). The Mode of Delivery and the Risk of Vertical Transmissionof Human Immunodeficiency Virus Type 1 - A Meta-Analysis of 15 Prospective Cohort Studies. New England Journal of Medicine, 1999;340:977-987.
  • Thorpe LE, Frederick M, Pitt J, Cheng I, Watts DH, Buschur S, Green K, Zorrilla C, Landesman SH, Hershow RC. Effect of hard-drug use on CD4 cell percentage, HIV RNA level, and progression to AIDS-defining class C events among HIV-infected women. J Acquir Immune Defic Syndr. 2004; 37(3):1423-30.
  • Tuomala RE, Watts DH, Li D, Vajaranant M, Pitt J, Hammill H, Landesman S, Zorrilla C, Thompson B; Women and Infants Transmission Study. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy.J Acquir Immune Defic Syndr. 2005; 38(4):449-73.
  • Magder LS, Mofenson L, Paul ME, Zorrilla CD, Blattner WA, Tuomala RE, LaRussa P, Landesman S, Rich KC. Risk factors for in utero and intrapartum transmission of HIV. J Acquir Immune Defic Syndr. 2005; 38(1):87-95
  • Navas-Nacher EL, Read JS, Leighty RM, Tuomala RE, Zorrilla CD, Landesman S, Rosenblatt H, Hershow RC; for the Women and Infants Transmission Study Group. Mode of delivery and postpartum HIV-1 disease progression: The Women and Infants Transmission Study. AIDS; 2006;20(3):429-436.
  • Read JS, Tuomala R, Kpamegan E, Zorrilla C, Landesman S, Brown G, Vajaranant M, Hammill H, Thompson B; Women and Infants Transmission Study Group. Mode of delivery and postpartum morbidity among HIV-infected women: the women and infants transmission study. J Acquir Immune Defic Syndr. 2001; 26(3):236-45.
  • Rawstron SA, Jackman JM, Serebro E, Johnson G, Cabbad M, Bromberg K, Kondamudi V, Sepkowitz D, Landman D. Perirectal screening for carbapenem-resistant Enterobacteriaceae obtained from 100 consecutive healthy pregnant women in labor at a Brooklyn hospital: Results and risk factors. Infect Control Hosp Epidemiol 2018; 39:369-71.
  • Nath S, Moussavi F, Abraham D, Landman D, Quale J. In vitro and in vivo activity of single and dual antimicrobial agents against KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother 2018; 73:431-6.
  • Manning N, Balabanian G, Rose M, Landman D, Quale J. Activity of ceftazidime-avibactam against clinical isolates of Klebsiella pneumoniae, including KPC-carrying isolates, endemic to New York City. Microb Drug Resist 2018; 24:35-9.
  • Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D, Ghitan M, Collins B, Bratu S, Quale J. Rise and fall of KPC-producing Klebsiella pneumoniae in New York City. J Antimicrob Chemother 2016; 71:2945-8.
  • Lapuebla A, Abdallah M, Olafisoye O, Cortes C, Urban C, Quale J, Landman D. Activity of meropenem combined with RPX7009, a novel β-lactamase inhibitor, against Gram-negative clinical isolates in New York City. Antimicrob Agents Chemother 2015; 59: 4856-60.

Department Links

Infectious Diseases